{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:37:55Z","timestamp":1788089875440,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,18]]},"DOI":"10.7759\/cureus.109159","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:15:47Z","timestamp":1779171347000},"source":"Crossref","is-referenced-by-count":1,"title":["Checkpoint Inhibitor-Induced Raynaud\u2019s Phenomenon, Hypothyroidism, and Pneumonitis in Head and Neck Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Levente","family":"Bodoki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamas","family":"Csonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szilvia","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00f3ra Anna","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese LH","year":"2018","unstructured":"Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018, 14:569-79. 10.1038\/s41584-018-0074-9","journal-title":"Nat Rev Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1556\/650.2019.31392","article-title":"Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment","volume":"160","author":"Szekanecz \u00c9","year":"2019","unstructured":"Szekanecz \u00c9, Szekanecz Z. Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment. Orv Hetil. 2019, 160:887-95. 10.1556\/650.2019.31392","journal-title":"Orv Hetil"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1252215","article-title":"Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience","volume":"13","author":"Sebesty\u00e9n E","year":"2023","unstructured":"Sebesty\u00e9n E, Major N, Bodoki L, et al.. Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience. Front Oncol. 2023, 13:1252215. 10.3389\/fonc.2023.1252215","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.010","article-title":"Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Tocut M","year":"2018","unstructured":"Tocut M, Brenner R, Zandman-Goddard G. Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018, 17:610-6. 10.1016\/j.autrev.2018.01.010","journal-title":"Autoimmun Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","author":"Postow MA","year":"2015","unstructured":"Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015, 76-83. 10.14694\/EdBook_AM.2015.35.76","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review","volume":"64","author":"Khan S","year":"2020","unstructured":"Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol. 2020, 64:93-101. 10.1016\/j.semcancer.2019.06.012","journal-title":"Semin Cancer Biol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine M","year":"2021","unstructured":"Kostine M, Finckh A, Bingham CO, et al.. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021, 80:36-48. 10.1136\/annrheumdis-2020-217139","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman CF","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016, 2:1346-53. 10.1001\/jamaoncol.2016.1051","journal-title":"JAMA Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00333","article-title":"Raynaud's phenomenon from PD-1 immune checkpoint inhibition","volume":"16","author":"Kim H","year":"2020","unstructured":"Kim H, Jones AJ, Labadzhyan A, Placencio-Hickok VR, Wallace DJ, Gong J, Hendifar AE. Raynaud's phenomenon from PD-1 immune checkpoint inhibition. JCO Oncol Pract. 2020, 16:701-2. 10.1200\/JOP.19.00333","journal-title":"JCO Oncol Pract"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.004","article-title":"Tumor-associated Raynaud's phenomenon exacerbated by administration of immune checkpoint inhibitors","volume":"17","author":"Sumi T","year":"2022","unstructured":"Sumi T, Michimata H, Nagayama D, Koshino Y, Watanabe H, Yamada Y, Chiba H. Tumor-associated Raynaud's phenomenon exacerbated by administration of immune checkpoint inhibitors. J Thorac Oncol. 2022, 17:1233-4. 10.1016\/j.jtho.2022.07.004","journal-title":"J Thorac Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/484384-checkpoint-inhibitor-induced-raynauds-phenomenon-hypothyroidism-and-pneumonitis-in-head-and-neck-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:15:50Z","timestamp":1779171350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/484384-checkpoint-inhibitor-induced-raynauds-phenomenon-hypothyroidism-and-pneumonitis-in-head-and-neck-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.109159","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}